卡特科尔-素纳米颗粒使铁饥饿和细菌亲和力为向性肝脏清除金黄色葡萄球菌
Tiannuo Wu1, Boyang Yang2, Xiaojie Yao2
1School of Medicine, Guangxi University, Nanning 530004, China.
ACS applied materials & interfaces
|February 12, 2026
概括
这项研究开发了新的脂质纳米颗粒,用于输送多西环素,增强细菌向和肝脏保留,以提高疗效和减少细菌负荷,有效治疗金黄色葡萄球菌感染.
科学领域:
- 纳米医学是一种纳米医学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于黄金葡萄球菌感染的传统抗生素治疗,其细菌向性较差,肝脏保留性有限.
- 开发先进的药物输送系统对于克服这些局限性和改善治疗结果至关重要.
研究的目的:
- 开发和评估载有多西环素 (DX@CSCNP) 的脂质纳米颗粒,用于增强治疗黄菌诱导的肝脏感染.
- 调查该新型纳米输送系统的抗菌疗效,向能力和药物动力学特征.
主要方法:
- 脂质纳米颗粒 (DX@CSCNP) 通过自组装使用甲基醇修饰的奇托和大豆脂构建.
- 通过确定针对S. aureus的最小抑制度 (MIC) 来评估体外抗菌活性.
- 在体内研究包括评估S. aureus感染的小鼠模型中的药物分布,肝脏积累和治疗疗效.
主要成果:
- DX@CSCNP表现出增强的体稳定性,颗粒大小为~150nm,封装效率>85%.
- 实验室研究表明,DX@CSCNP实现了S. aureus的快速根除,MIC显著降低,与自由多西环素相比.
- 在体内研究表明,在接受DX@CSCNP治疗的感染小鼠中,肝脏保留时间长,肝脏细菌负荷显著降低.
结论:
- 开发的DX@CSCNP系统提供了一种协同方法,用于通过向输送,延长肝脏保留和增强药物释放来治疗黄金色肝炎感染.
- 这种纳米输送系统代表了针对深层细菌感染的向纳米治疗的有希望的战略.
相关概念视频
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
550
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
550
Hepatic Drug Clearance: Role of Transporters
312
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
312
Hepatic Drug Clearance: Effect of Protein Binding
566
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
566
Affinity and Avidity
39.3K
Overview
39.3K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
304
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
304
Electron Affinity
43.7K
The electron affinity (EA) is the energy change for adding an electron to a gaseous atom to form an anion (negative ion).
43.7K


